Objectives Metallo-β-lactamase (MBL)-producing Enterobacterales are a major challenge
worldwide due to limited treatment options. Aztreonam-avibactam (ATM-AVI), which is under …

Objectives: Infections caused by drug-resistant Enterobacterales including those producing
metallo-β-lactamases (MBLs) are particularly challenging due to limited therapeutic options …

Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested
for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing …

Objectives To study the molecular epidemiology of clinical metallo-β-lactamase (MBL)-
producing Enterobacteriaceae isolates in China and to evaluate the antimicrobial …

Increasing antimicrobial resistance among multidrug-resistant (MDR), extended-spectrum β-
lactamase (ESBL)-and carbapenemase-producing Enterobacterales (CPE), in particular …

Background Aztreonam is a monobactam stable to hydrolysis by metallo-β-lactamases
(MBLs) and avibactam is a non-β-lactam β-lactamase inhibitor that effectively inhibits serine …

ABSTRACT Metallo-β-lactamase (MBL)-producing Enterobacterales are of particular
concern because they are widely disseminated and difficult to treat, being resistant to almost …

This study aimed to report reference method antimicrobial susceptibility results for 24,937
recent (2019–2021) clinical isolates of Enterobacterales from 27 countries in Latin America …

Background Aztreonam/avibactam is under development to treat infections caused by Gram-
negative bacteria. We evaluated the in vitro activities of aztreonam/avibactam and …

Cefiderocol and aztreonam-avibactam (ATM-AVI) both had activity against carbapenem-
resistant Gram-negative bacilli, including those that produce metallo-β-lactamases (MBLs) …